International Germ Cell Cancer Collaborative Group / /
Country
United States / /
Currency
pence / /
Facility
Memorial Sloan-Kettering Cancer Center / /
IndustryTerm
integrated staging systems / care for muscle-invasive bladder cancer / tumor suppressor gene product / risk algorithm / care for muscle-invasive disease / treatment of metastatic disease / cancer care / therapy for superficial bladder cancer / /
MedicalCondition
clear-cell carcinoma / bladder tumor / JE / seminoma and malignant teratoma / Superficial tumors / I testis cancer / bladder cancer / Von Hippel-Lindau tumor / metastatic disease / high-grade tumors / muscle-invasive disease / renal cancer / previously untreated and relapsed disease / relevant tumor / renal cell carcinoma / midline tumors / Superficial and muscle-invasive bladder cancer / germ cell tumors / invasive bladder cancer / low-grade tumors / metastatic renal cell cancer / tumor / superficial urothelial cancer / both tumor / cancer / tumors / disseminated germ-cell tumors / disease / muscle-invasive bladder cancer / metastatic renal cell carcinoma / I seminoma and nonseminomatous GCTs / Testicular germ-cell cancer / progressive disease / CANCERS Bladder cancer / good-risk disease / metastatic germ cell cancers / advanced germ cell tumors / advanced bladder cancer / urothelial cancer / adult male germ cell tumors / metastatic transitional cell carcinoma / urothelial cancers / advanced seminoma / seminoma / advanced transitional cell carcinoma / superficial bladder cancer / primary tumor / hereditary papillary RCC / /
American Society of Clinical Oncology / American Society of Clinical Oncology REFERENCES / Department of Medicine / US Food and Drug Administration / Memorial Sloan-Kettering Cancer Center / /
Person
Dean F. Bajorin / Robert J. Motzer / George J. Bosl / /
Position
Author / /
Product
cisplatin / etoposide / /
ProvinceOrState
New York / /
PublishedMedium
the Journal of Clinical Oncology / Journal of Clinical Oncology / /